membahas tentang kegawatab Paru

1. 1
KEGAWATAN PENYAKIT DALAM
Fenny Febrianty
Internal Medicine Department
Medical Faculty, Jambi University

2. 2
Topik pembicaraan
• Kegawatan paru
– Pneumotoraks
– Hemoptisis
– Status asthmatikus

3. 3
PNEUMOTORAKS

4. 4

5. 5
Definition
The accumulation of
air in the pleural
space with secondary
collapse of the
surrounding lung.

6. 6
Classification
• Spontaneous pneumothorax
– Primary spontaneous pneumothorax
Occurs without a precipitating event in a person
with no clinical evidence of lung disease
– Secondary spontaneous pneumothorax
Occurs as a complication of underlying lung
disease (most often COPD)
• Traumatic pneumothorax
– Iatrogenic pneumothorax

7. 7
Etiology of Secondary Spontaneous
Pneumothorax
• Obstructive lung disease (COPD, Asthma)
• Interstitial lung disease (IPF, Non-specific interstitial
pneumonitis, eosinophillic granuloma, sarcoidosis, etc)
• Infection (pneumonia, tuberculosis)
• Malignancy (lung cancer, pulmonary metastasis,
complications of chemotherapy)
• Connective tissue disease (RA, ankylosing spondylitis,
Marfan’s syndrome, scleroderma)
• Other (Catamenial, pulmonary infarction, PAP, etc)

8. 8
Tension pneumothorax
• A tension pneumothorax is a medical emergency as air
accumulates in the pleural space with each breath. The
increase in intrathorasic pressure results in massive
shifts of the mediastinum away from the affected lung
compressing intrathorasic vessels
• Severe tachycardia (Heart rate >140 beats/ mnt)
• Hypotension
• Cyanosis,
• Tracheal deviation

9. 9
Tension pneumothorax

10. 10
Proposed mechanism of alveolar rupture
in spontaneous pneumothorax
A. Normal structures B. Overdistention of
marginal alveoli

11. 11
Clinical signs
• May be asymptomatic
• Chest pain
Acute, localized to the side of the pneumothorax, and
typically pleuritic
• Dyspnea/orthopnea (lung and cor problem)
• Cough
• Hemoptysis
• Cyanosis
• Subcutaneous emphysema
• Symptoms in secondary spontaneous pneumothorax
more severe than patients with PSP

12. 12
Pneumothorax
I. S. Cembung sisi sakit
D. Tertinggal
P. Fremitus turun sampai
hilang
P. Hipersonor
A. Suara napas lemah
sampai hilang
Pada small pneumothorax PD dapat normal
Sukar dibedakan dengan PPOK

13. 13
Physiological consequences
• Decrease of vital capacity
• Decrease of PaO2
• Decrease of total lung capacity
• Decrease of functional residual capacity
• Reduce of diffusing capacity
Coma, Death

14. 14
Radiology
Spontaneous pneumothorax.
The visceral pleural line is clearly
seen with the absence of vascular
workings beyond the pleural line.

15. 15
Estimation of the size of pneumothorax

16. 16
Treatment
• The basic tenets of therapy for pneumothoraces are to
evacuate the space, achieve closure of the leak, and
either prevent or reduce this risk
• The choice of treatment
– Observation
Asymptomatic patient; Small unilateral pneumothorax
Asses for further progression
– Simple aspiration
– Tube thoracostomy/WSD (Simple; Continuous suction)
– Pleurodesis
– Thoracoscopy
– Surgical

17. 17
Tube thoracostomy/WSD

18. 18
3 bottle chest tube drainage system

19. 19

20. 20
Status asthmaticus

21. 21

22. 22
Mechanisms Underlying the
Definition of Asthma
Risk Factors
(for development of asthma)
INFLAMMATION
Airway
Hyperresponsiveness Airflow Obstruction
Risk Factors
(for exacerbations)
Symptoms

23. 23
Astma ringan Asthma sedang Asthma berat
Sesak napas Waktu berjalan
Bisa berbaring
Waktu berbicara
Lebih suka duduk
Saat istirahat
Duduk membungkuk
Berbicara Kalimat Kata-kata Kata demi kata
Kesadaran Mungkin agitasi Biasanya agitasi Biasanya agitasi
RR < 20 x 20 – 30 x > 30 x / menit
Nadi < 100 kali/menit 100-120 x/menit > 120 kali/menit
Pulsus
paradoksus
Tidak ada Mungkin ada Biasanya ada
Otot bantu
napas
Biasanya tidak Biasanya ada Biasanya ada
Mengi Akhir ekspirasi Akhir ekspirasi Sepanjang ekspirasi
Klasifikasi asthma akut

24. 24
Astma ringan Asthma
sedang
Asthma berat
APE %
terhadap
standard
> 70-80% 50 - 70% < 50%
PO2 Normal > 60 mmHg < 60 mmHg
(mungkin sianosis)
PCO2 < 45 mmHg < 45 mmHg > 45 mmHg
SO2 > 95% 91-95% < 90%
Klasifikasi asthma akut

25. 25
Definition
Severe attack of asthma poorly responsive to
adrenergic agents and associated with signs or
symptoms of potential respiratory failure

26. 26
Asthma mengancam jiwa
• Tidak begitu sadar
• Pemakaian otot bantu napas
• Pergerakan torako abdominal yang
paradoksal
• Tidak ada mengi
• Bradikardi
• Tidak ada pulsus paradoksus (otot napas
sudah lelah)

27. 27
Clinical Danger Signs
• Use of accessory muscles of respiration
• Brief, fragmented speech
• Inability to lie supine
• Profound diaphoresis
• Agitation
• Severe symptoms that fail to improve with initial
emergency department treatment
• Life-threatening airway obstruction can STILL OCCUR
when these signs are not present

28. 28
Diagnosis
• Hx: most powerful predictor that this may be life-threatening
is a prior intubation for an asthma attack
• PEX: alteration in consciousness, fatigue, upright posture,
diaphoresis, accessory muscle breathing.
– Tachycardia, tachypnea, pulsus paradoxus
– IMPORTANT: look in the mouth as obstruction might be
in the upper airway (epiglottitis, angioedema)
• Peak Flow (PEFR): if pt is not too dyspneic. Best measure
of severity

29. 29
Diagnosis
• ABG: Look at PaCO2. Resp drive almost always increased
in acute asthma  hyperventilation  decreased PaCO2.
– Thus, an elevated or normal PaCO2 indicates airway
narrowing is so severe that the ventilatory demands
cannot be met. Failure is imminent
• CXR: usually not helpful
– Obtain if diagnosis is in doubt, patient is high-risk
(IVDU, immunosuppressed, chronic pulmonary
disease), or if complications are suspected
(pneumothorax)

30. 30
Resiko tinggi asthma berat
• Sedang / baru saja lepas dari pemakaian steroid
sistemik
• Mempunyai riwayat rawat inap dlm waktu 12
bulan terakhir
• Riwayat intubasi karena asma
• Mempunyai masalah psikososial atau psikiatri
• Ketidaktaatan pengobatan asma

31. 31
Penilaian Pertama : Tentukan berat ringannya serangan asma (lihat tabel 1)
Penanganan Permulaan :
- Inhalasi short acting -2 agonist dengan nebulisasi, 1 dosis selama 20’ dlm 1 jam.
- Oksigen untuk mencapai saturasi 0 – 90% (95% pada anak-anak)
- Kortikosteroid sistemik, jika tidak ada respons segera atau jika ada pasien baru
mendapat steroid per oral, atau jika serangan asmanya berat
- Sedasi merupakan kontra indikasi pada penanganan serangan akut / eksaserbasi
Ulangi Penilaian
Serangan Asma Sedang :
- APE 5–70% dari nilai yg diperkirakan
nilai terbaik
- Pemeriksaan fisik Asma sedang, otot
bantu
- Inhalasi Agonis  - 2 setiap 60’
- Pertimbangkan kortikosteroid
- Ulangi pengobatan 1 – 3 jam
Serangan Asma Berat :
- APE < 50% nilai terbaik
- Pemeriksaan fisik sama berat saat istirahat
- Riwayat pasien resiko tinggi
- Inhalasi Agonis -2 tiap jam atau
kontinue inhalasi anti kolinergik
- Oksigen
- Kortikosteroid sistemik
- Pertimbangan Agonis  - 2 Sc, IM atau IV
Pengelolaan Serangan Asma di Rumah Sakit Menurut GINA

32. 32
Respon Baik
- Respon selama 60’ sesudah
terapi terakhir
- Pemeriksaan fisik normal,
APE > 70%
- Tidak ada distress
-Saturasi O2 > 90% (anak 95%)
Respon tdk baik dlm 1-2 jam
- Riwayat pasien risiko
tinggi
- Pem.fisik : gejala ringan /
sedang
- APE > 50%, tapi < 70 %
- Saturasi O2 tidak membaik
Respon Buruk dlm 1 jam
- Riwayat : risiko tinggi
- Pemeriksaan fisik :
Asma berat, mengantuk
- APE < 30%
- PCO2 > 45 mmHg
- PO2 < 60 mmHg
Dipulangkan :
-Lanjutkan pengobatan & Agonis
 - 2 inhalasi
- Pertimbangkan kortikosteroid
oral (pd kebanyakan pasien)
- Pendidikan pasien
- Minum obat secara benar
- Tinjau lagi rencana kerja
(action plan)
- Tindak lanjut pengobatan yg
ketat
Dirawat di RS (ruang biasa)
- Inhalasi agonis  - 2 
inhalasi antikolinergik
- Kortikosteroid
- Oksigen
- Pertimbangan Aminofilin IV
- Pantau APE, saturasi O2,
nadi, teofilin
Rawat di ICU :
- Inhalasi Agonis  - 2 
antikolinergik
- Kortikosteroid IV
- Pertimbangkan Agonis
-2 Sc, IM dan IV
- Intubasi dan ventilasi
mekanik

33. 33
Perbaikan Tidak ada perbaikan
Dipulangkan
Jika APE 50% dan terus menerus
dalam pengobatan peroral / inhalasi
Masuk ICU
Jika tidak ada perbaikan dalam
6 – 12 jam

34. 34
Emergency therapy of the asthma exacerbation
Asthma patient with
severe symptoms
Clinical Evaluation
First-Line Therapy
Second-Line Therapy
Third-Line Therapy
Consider causes
A. Oxygen B. Monitor C. Obtain
A. Beta-2 agonist B. IV Corticosteroid
Subcutaneous Beta Agonist
(Epinephrine or Terbutaline)
Methylxanthines
(Aminophylline/Theophylline)
A

35. 35
Adjunctive therapy A. Ipratropium
Bromide
B. Antibiotics C. Magnesium
Sulfate
A
PROCEED FUTHER IN THE SETTING
OF PATIENT DETERIORATION DESPITE
MAXIMAL MEDICAL THERAPY
Intubation and Mechanical
Ventilation
Intubation and Mechanical Ventilation
Considerations
Postintubation Therapy Step 1 Therapy : Sedation
Step 2 Therapy : IV Ketamine
Step 3 Therapy : General inhalation anesthesia
(avoid halothane)
Step 4 Therapy : Extracorporeal lung assist

36. 36
HEMOPTYSIS

37. 37
Definition
• The spitting of blood derived from the lungs or
bronchial tubes as a result of pulmonary or bronchial
hemorrhage
• Based on the volume of blood loss: Massive and non
massive
Only 5% of hemoptysis is massive but mortality is
80%.
• Massive
– Blood lose > 600 ml / day
– Blood lose < 600 ml / day, but > 250 ml, Hb < 10 g% and
hemoptysis still continue
– Blood lose < 600 ml / day, but > 250 ml, Hb > 10 g% and
hemoptysis still continue in 48 hours

38. 38
Differentiating Features of
Hemoptysis and hematemesis

39. 39
Etiology
• Infection (bronchitis, pneumonia, lung tuberculosis,
HIV)
• Lung cancer (include metastatic lesions)
• Old tuberculosis
• Pulmonary venous hypertension (LV heart failure, MS,
Pulmonary emboli)
• Idiopathic

40. 40

41. 41
Diagnostic Clues in Hemoptysis: Physical History

42. 42
Physical Examination
• Vital signs
• Constitutional signs (cachexia, level of distress)
• Skin and mucous membranes
• Lymph node
• Cardiovascular examination
• Lung examination
• Abdominal examination
• Extremities

43. 43
Physical Examination
• Telangiectasias (hereditary hemorrhagic telangiectasia)
• Skin rash (vasculitis, SLE, fat embolism, infective
endocarditis)
• Splinter hemorrhages (endocarditis, vasculitis)
• Clubbing (chronic lung diseases)
• Chest bruit or murmur that increases with inspiration
(large pulmonary AV malformations)
• Cardiac murmurs (congenital heart disease,
endocarditis with septic emboli, mitral stenosis)
• Legs (Deep venous thrombi)

44. 44

45. 45
Komplikasi
• Asfiksia
• Kegagalan kardiosirkulasi ( hipovolemi )
• Setiap batuk darah sebaiknya dirawat kecuali “blood
streak”
• Perlu evaluasi :
– Banyaknya perdarahan
– Pemeriksaan fisik
– Pemeriksaan foto toraks
– Pemeriksaan laboratorium ( segera )

46. 46
Management (1)
Difficult
• Multitude of potential etiologies.
• Course of bleeding is unpredictable.
• It is frightening to see patients dying from asphyxiation,
even in spite of intubation.
• There is no consensus regarding the optimal
management of these patients

47. 47
Management (2)
• Adequate airway protection, ventilation, and
cardiovascular function
• Intubate if pt. has poor gas exchange, rapid ongoing
hemoptysis, hemodynamic instability, or severe
shortness of breath
• Reverse coagulation disorders
• A major priority in the acute management in protection
of the non-bleeding lung.
• Spillage of blood into the non-bleeding lung can either
block the airway with clot or fill the alveoli and prevent
gas exchange.

48. 48
Management (3)
Protection of non-bleeding lung
• Place bleeding lung in the dependant position
• Selectively intubate the non-bleeding lung- easiest if
you want to intubate right main stem bronchus during
a left lung bleed.
• Balloon tamponade via bronchoscopy
• Placement of a double lumen ETT specially designed
for selective intubation of the right or left main stem
bronchi

49. 49
Management (4)
• Management with Bronchoscopy
– Lavage with iced saline and application of topical epinephrine
(1:20,000), vasopressin, thrombin, or a fibrinogen-thrombin
combination.
• Arterial embolization
– 85% of the time the bleeding stops after embolization
– 10-20% of patients re-bleed in the following 6-12 months
• Surgery
– Lower mortality
– Highest risk patients were not considered to be surgical
candidates and were managed medically (active TB, cystic
fibrosis, diffuse alveolar hemorrhage)

50. 50
TERIMAKASIH